CLOs on the Move

Canopy Health Insurance

www.covermecanopy.com

 
We do things differently here. Unlike old-school health insurance, ours is refreshingly simple, wallet-friendly and designed for your life. It’s health insurance you just might like.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Marlette Regional Hospital

Marlette Regional Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Marlette, MI. To find more information about Marlette Regional Hospital, please visit www.mrhcares.org

Edward Hospital and Health Services Corporation

Edward Hospital & Health Services is a full-service, regional health care organization, offering access to a wide variety of complex medical specialties and innovative programming.

JPS Health Network

JPS Health Network is a $950 million, tax-supported health care system for Tarrant County in North Texas. Anchored by a 537-bed acute care hospital, the network includes more than 46 community-based clinics, including 20 school-based clinics. John Peter Smith Hospital is home to Tarrant County`s first and only Level 1 Trauma Center, its only psychiatric emergency services site and has the largest family medicine residency program in the nation. Our network employs more than 6,500+ people.

Vegreville and District Family and Community Support Services

Vegreville & District Family and Community Support Services is a Vegreville, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.